AUS
NZ
UK
CA
USA
IND
Highlights
- Cyclopharm (ASX:CYC) secures agreements with major US healthcare networks for its lung imaging technology, Technegas.
- Technegas is operational in 66 countries, demonstrating extensive global adoption.
- The US market, valued at up to $900 million, presents expansion opportunities in areas such as COPD and hypertension.
Cyclopharm (ASX:CYC) has established a foothold in the US healthcare market following FDA approval for Technegas, its advanced lung imaging technology. This milestone follows a 16-year approval process, during which Technegas has gained widespread adoption across 65 countries, including Canada. With US regulatory clearance secured, the company is rapidly advancing its commercialization efforts by forging partnerships with leading public and private healthcare networks.
Major Healthcare Collaborations
Cyclopharm has partnered with the Veterans Health Administration (VA), the largest integrated healthcare system in the US, to supply Technegas for pulmonary embolism detection. Additionally, the company has secured a preferred supplier agreement with Health Corporation of America (HCA), the largest non-governmental hospital network in the country. These collaborations enhance access to nuclear medicine departments, the primary domain for Technegas applications.
Competitive Advantage and Clinical Benefits
Technegas provides a highly accurate, low-radiation solution for pulmonary embolism detection, positioning it as a preferred alternative to conventional CT scans. Its efficacy extends to conditions such as chronic obstructive pulmonary disease (COPD) and asthma, enhancing diagnostic precision. Furthermore, reimbursement support from the Centers for Medicare and Medicaid Services (CMS) strengthens its attractiveness within the US healthcare system.
Market Potential and Future Growth
The pulmonary embolism detection market in the US is valued at approximately $180 million, with broader applications in conditions such as hypertension potentially expanding its reach. Installations at leading institutions like Massachusetts General Hospital and Stanford University Hospital highlight Technegas’ growing acceptance among top-tier medical facilities.
Addressing Challenges and Ensuring Growth
While advancing its US presence, Cyclopharm remains aware of geopolitical and trade-related risks. To mitigate potential disruptions, the company is exploring secondary manufacturing outside Australia, reinforcing its supply chain resilience. With over 30 years in the life sciences sector, Cyclopharm is strategically positioned to strengthen its role in nuclear medicine imaging.
Outlook
Cyclopharm’s expansion underscores its adaptability and long-term growth strategy. With strong market positioning, strategic alliances, and a commitment to innovation, the company is set to capitalize on the vast opportunities within the US healthcare sector and beyond.
